ILLUMINA, INC.
ILMN US4523271090
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Thaysen Jacob CEO |
81.56 USD |
804 Bought |
65,574 USD |
12/05/2025 | 13/05/2025 |
Thaysen Jacob CEO |
81.56 USD |
804 Bought |
65,574 USD |
12/05/2025 | 13/05/2025 |
Thaysen Jacob CEO |
80.70 USD |
4,946 Bought |
399,142 USD |
12/05/2025 | 13/05/2025 |
Thaysen Jacob CEO |
82.26 USD |
100 Bought |
8,226 USD |
12/05/2025 | 13/05/2025 |
Thaysen Jacob CEO |
80.70 USD |
4,946 Bought |
399,142 USD |
12/05/2025 | 13/05/2025 |
Thaysen Jacob CEO |
82.26 USD |
100 Bought |
8,226 USD |
12/05/2025 | 13/05/2025 |
Thaysen Jacob CEO |
79.70 USD |
1,200 Bought |
95,640 USD |
12/05/2025 | 12/05/2025 |
Thaysen Jacob CEO |
82.66 USD |
200 Bought |
16,532 USD |
12/05/2025 | 12/05/2025 |
Thaysen Jacob CEO |
81.54 USD |
1,400 Bought |
114,156 USD |
12/05/2025 | 12/05/2025 |
Dhingra Ankur SR VP |
81.21 USD |
6,100 Bought |
495,381 USD |
12/05/2025 | 12/05/2025 |